Related Experiment Video
Updated: Feb 19, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
[Clinical trials and perspectives of radiotherapy for uterine endometrial cancers]
Cyrus Chargari1, Pierre Maroun2, Ioana Lazarescu2
1Gustave-Roussy Cancer Campus, service de curiethérapie, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Gustave-Roussy Cancer Campus, radiothérapie moléculaire, UMR 1030, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Institut de recherche biomédicale des armées, D19, effets biologiques des rayonnements, 91220 Brétigny-sur-Orge, France; École du Val-de-Grâce, 1, place Alphonse-Laveran, 75230 Paris cedex 05, France.
Abstract:
The adjuvant management of uterine endometrial cancer has been studied in many randomized trials, leading to define postoperative therapeutic indications, depending on the risk factors for relapse, and on the expected benefit in terms of locoregional control and survival. The potential toxicity of treatments should be also considered. We review the available literature that yielded to guidelines that were recently published, on behalf of European societies, and we highlight the perspectives on ongoing studies, aimed at better defining the place and type of adjuvant treatment.
